Sangamo BioSciences | SGMO - Capital Ordinário





Capital Ordinário Alterar Data
Alaunos Therapeutics USD 2.38M 172K 2026-03
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Alterity Therapeutics Limited AUD 10.88B 10.66B 2025-12
Amgen USD 540M 1000K 2026-03
Bayer EUR 982.42M 0 2025-12
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Cipla INR 807.78M 17K 2026-03
Clal Biotechnology ILS 1.61M 0 2022-12
Compugen USD 94.55M 1000 2026-03
CSL USD 482.13M 93.87M 2025-12
Gilead Sciences USD 1.24B 1000K 2026-03
GlaxoSmithKline GBP 4.05B 20.6M 2026-03
Grifols EUR 680.58M 846.11K 2025-12
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
J&J USD 2.41B 1.74M 2025-12
Karyopharm Therapeutics USD 18.31M 18.3M 2025-12
Merck USD 2.47B 12.72M 2025-12
Novartis USD 1.91B 60K 2026-03
Omeros USD 611K 17K 2023-12
Pfizer USD 5.7B 13M 2026-03
Roche Holding CHF 795.62M 699.54K 2025-12
Sanofi EUR 1.21B 8.25M 2026-03
Sarepta Therapeutics USD 105.57M 607K 2026-03
Tectonic Therapeutic USD 18.83M 92.19K 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 254.2M 200K 2026-03